Jeff Yass’s Satsuma Pharmaceuticals, Inc. Common Stock STSA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q2
Sell
-98,000
Closed -$68.6K 13642
2023
Q1
$68.6K Sell
98,000
-42,800
-30% -$39.4K ﹤0.01% 11536
2022
Q4
$127K Buy
140,800
+116,600
+482% +$338K ﹤0.01% 10705
2022
Q3
$145K Buy
+24,200
New +$137K ﹤0.01% 11291

Jeff Yass's STSA Position: Q1 2023 in Review

Jeff Yass sold out of Satsuma Pharmaceuticals, Inc. Common Stock (STSA) in Q1 2023, closing a stake of 54,419 shares — an estimated $50.1K sold.

Jeff Yass first reported a position in STSA in Q2 2020 and held it in 7 quarters. The position peaked at $432K in Q4 2021. 31 funds tracked by Wall St. Rank hold STSA as of Q1 2023.

  • Jeff Yass reported no remaining Satsuma Pharmaceuticals, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
  • Jeff Yass sold 54,419 Satsuma Pharmaceuticals, Inc. Common Stock shares in Q1 2023, an estimated $50.1K.
  • Jeff Yass first reported a position in Satsuma Pharmaceuticals, Inc. Common Stock in Q2 2020 and held it in 7 quarters.
  • Jeff Yass's Satsuma Pharmaceuticals, Inc. Common Stock position peaked at $432K in Q4 2021.
  • 31 funds tracked by Wall St. Rank held Satsuma Pharmaceuticals, Inc. Common Stock as of Q1 2023.

Based on Susquehanna International Group's 13F filing for Q1 2023, filed 16 May 2023.